<DOC>
	<DOCNO>NCT00363142</DOCNO>
	<brief_summary>This 24-week study evaluate efficacy safety once-daily ritonavir-boosted fosamprenavir regimen ( 1400mg/100mg QD ) 200mg ritonavir-boosted fosamprenavir regimen administer either twice-daily once-daily .</brief_summary>
	<brief_title>A Study Investigational Regimen Combining FDA Approved HIV Drugs HIV-Infected Subjects</brief_title>
	<detailed_description>A Phase IIIB , randomize , open-label , parallel group , multi-center , non-inferiority , 24-week study evaluate safety , efficacy tolerability switch 200mg ritonavir-boosted regimen LEXIVA ( 700mg/100mg BID 1400mg/200mg QD ) once-daily , 100mg ritonavir-boosted regimen LEXIVA ( 1400mg/100mg QD )</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<criteria>Inclusion criterion : Subjects HIV1 infection . Are willing able understand provide write consent prior participation study . Exclusion criterion : Are pregnant breastfeeding . Have active AIDS condition , pancreatitis , poor kidney function , clinically relevant hepatitis . Have certain medical condition may make participation unsafe . Take medication may interact study medication . Have history allergy study drug excipients therein . Other inclusion/exclusion criterion evaluate physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>HIV-1 LEXIVA Ritonavir Once-daily</keyword>
</DOC>